These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31178440)

  • 1. Budget impact of introducing tofacitinib to the public hospital formulary in Hong Kong, 2017-2021.
    Li X; Pathadka S; Man KK; Wong ICK; Chan EWY
    Hong Kong Med J; 2019 Jun; 25(3):201-208. PubMed ID: 31178440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States.
    Bungey G; Chang-Douglass S; Hsu MA; Cappelleri JC; Young P; Woolcott J
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1027-1038. PubMed ID: 32308099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.
    Claxton L; Taylor M; Gerber RA; Gruben D; Moynagh D; Singh A; Wallenstein GV
    Curr Med Res Opin; 2018 Nov; 34(11):1991-2000. PubMed ID: 29976110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
    Rendas-Baum R; Kosinski M; Singh A; Mebus CA; Wilkinson BE; Wallenstein GV
    Rheumatology (Oxford); 2017 Aug; 56(8):1386-1394. PubMed ID: 28460083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

  • 11. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.
    Garber K
    Nat Biotechnol; 2013 Jan; 31(1):3-4. PubMed ID: 23302910
    [No Abstract]   [Full Text] [Related]  

  • 12. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hong Kong domestic health spending: financial years 1989/90 to 2008/09.
    Tin KY; Tsoi PK; Lee YH; Tsui EL; Lam DW; Chui AW; Lo SV
    Hong Kong Med J; 2012 Aug; 18(4 Suppl 4):1-23. PubMed ID: 22947491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
    Park SK; Lee MY; Jang EJ; Kim HL; Ha DM; Lee EK
    Clin Exp Rheumatol; 2017; 35(4):689-699. PubMed ID: 28079510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.
    Camean-Castillo M; Gimeno-Ballester V; Rios-Sanchez E; Fenix-Caballero S; Vázquez-Real M; Alegre-Del Rey E
    J Clin Pharm Ther; 2019 Jun; 44(3):384-396. PubMed ID: 30729557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
    Wu B; Wang Z; Zhang Q
    Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
    Harnett J; Curtis JR; Gerber R; Gruben D; Koenig A
    Clin Ther; 2016 Jun; 38(6):1451-1463. PubMed ID: 27112534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.